Japanese Pharmaceutical Industry Realignment Speeds Up In 2008: Interview With President Of Dainippon Sumitomo
This article was originally published in PharmAsia News
In an interview with Yomiuri News, Dainippon Sumitomo President Kenjiro Miyatake noted 2008 drug prices are estimated to be over five percent lower
You may also be interested in...
TOKYO - BioSeek's deal last week with Danippon Sumitomo Pharma could be a model for additional deals between the Burlington, Calif.-based platform company and Japanese pharmas looking to de-risk preclinical decisions, according to BioSeek VP-Technology & Alliances Ivan Plavec
Avadim Health argues National Advertising Division expects substantiation for its homeopathic topical claims at the same level FDA requires for NDAs. NAD also said although FTC’s competent, reliable scientific evidence standard is “flexible” to some degree, pain claims are held to a more rigid standard.
With Roche's oral spinal muscular atrophy therapy Evrysdi off to a strong start after its recent US launch, Novartis is switching its priorities for rival RNA-splicing drug branaplam and putting it into a Phase IIb trial for Huntington's disease.